Trilaciclib Dihydrochloride Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Trilaciclib Dihydrochloride Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 24 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Trilaciclib Dihydrochloride can convert its Small molecule drug profile and CDK4 x CDK6 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Trilaciclib Dihydrochloride (query alias: Trilaciclib Dihydrochloride) |
|---|---|
| Modality / target | Small molecule drug; CDK4 x CDK6; CDK4 inhibitors, CDK6 inhibitors |
| Highest global status | Approved |
| Originator | G1 Therapeutics, Inc. |
| Active developers | Simcere Zaiming Pharmaceutical Co., Ltd., Pharmacosmos A/S, Patheon Manufacturing Services LLC |
The MCP disease footprint includes Extensive stage Small Cell Lung Cancer, Chemotherapy-induced myelosuppression, Small cell lung cancer limited stage. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| ChiCTR2600128499 | Phase 4 | Not yet recruiting | 33 | Incidence of neutropenia during neoadjuvant chemotherapy |
| CTR20262087 | Phase 3 | 进行中 （尚未招募） | 106 | Not disclosed |
| NCT07679997 | Phase 2 | Not yet recruiting | 32 | Incidence of grade ≥3 neutropenia during first-line treatment. |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
Trilaciclib for myeloprotection in adjuvant and first-line chemotherapy for advanced gastric/gastroesophageal junction adenocarcinoma: A multicohort study.
Phase 4; n=204; evaluation: Positive. Reported fields: Incidence of grade ≥3 neutropenia = 1.73 % ; Incidence of grade ≥3 neutropenia = 3.24 %
427P - Interim results of a randomized phase II trial of trilaciclib combined with envafolimab, etoposide, and carboplatin as first-line treatment for extensive-stage small cell lung cancer
Phase 2; n=52; evaluation: Positive. Reported fields: Hematologic toxicity(grade ≥4) = 30.8 % ; Hematologic toxicity(grade ≥4) = 3.8 %
A prospective, single-arm phase II study of trilaciclib combined with immunotherapy and chemotherapy as first-line treatment for metastatic/recurrent esophageal squamous cell carcinoma.
Phase 2; n=10; evaluation: Positive. Reported fields: AE = Other AEs were mainly grade 1-2, including decreased appetite (50%), fatigue (40%), headache (40%), and alopecia (10%).
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Trilaciclib Dihydrochloride addresses Extensive stage Small Cell Lung Cancer, Chemotherapy-induced myelosuppression, Small cell lung cancer limited stage. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 4 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2024-08-07 | Pharmacosmos Group and G1 Therapeutics Announce Successful Closing of Tender Offer | Approved | US$405.0M stated total |
| 2020-08-03 | G1 Therapeutics and Simcere Announce Exclusive License Agreement for Trilaciclib in Greater China | NDA/BLA | US$14.0M upfront; US$156.0M milestones |
| 2020-06-30 | G1 Therapeutics and Boehringer Ingelheim Announce Co-Promotion Agreement for Trilaciclib in Small Cell Lung Cancer in the United States and Puerto Rico | Phase 2 | Financial terms not disclosed |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Therapeutic index across KRAS/BRAF mutation subgroups
- On-target toxicity and adaptive MAPK resistance
- Lack of matched efficacy results in the current MCP result set
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 24 July 2026. Counts and status fields may change as source records update.
